Business Description
SpringWorks Therapeutics Inc
NAICS : 325412
SIC : 2834
100 Washington Boulevard, Stamford, CT, USA, 06902
Description
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 57.86 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -4.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -62.5 | |||||
| 3-Year EPS without NRI Growth Rate | -21.5 | |||||
| 3-Year FCF Growth Rate | -60.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.7 | |||||
| 9-Day RSI | 48.52 | |||||
| 14-Day RSI | 50.22 | |||||
| 6-1 Month Momentum % | -49.75 | |||||
| 12-1 Month Momentum % | -60.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | |||||
| Quick Ratio | 9.8 | |||||
| Cash Ratio | 9.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -54.58 | |||||
| ROA % | -50.89 | |||||
| ROIC % | -380.67 | |||||
| ROC (Joel Greenblatt) % | -3178.11 | |||||
| ROCE % | -54.08 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.64 | |||||
| Price-to-Tangible-Book | 4.63 | |||||
| EV-to-EBIT | -5.21 | |||||
| EV-to-EBITDA | -5.23 | |||||
| EV-to-FCF | -6.64 | |||||
| Price-to-Net-Current-Asset-Value | 5 | |||||
| Price-to-Net-Cash | 5.13 | |||||
| Earnings Yield (Greenblatt) % | -19.2 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:SWTX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -4.67 | ||
| Beta | 0 | ||
| Volatility % | 77.18 | ||
| 14-Day RSI | 50.22 | ||
| 14-Day ATR ($) | 3.041896 | ||
| 20-Day SMA ($) | 30.912 | ||
| 12-1 Month Momentum % | -60.78 | ||
| 52-Week Range ($) | 13.6 - 80.72 | ||
| Shares Outstanding (Mil) | 49.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SpringWorks Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||